Achillion Pharmaceut (NASDAQ:ACHN) shares traded 1.68% up during most recent session to reach at the closing price of $4.23. The stock exchanged hands 2.45 Million shares versus average trading capacity of 1.48 Million shares, yielding a market cap of $578.33 Million. Wall Street analysts covering the stock are projecting that the stock will reach $6.75 within the next 52-weeks. The mean target projections are based on 8 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Achillion Pharmaceut (NASDAQ:ACHN) high price target of $13 and with a conservative view have low price target of $5.

Leerink Swann “Upgrades” Achillion Pharmaceut (NASDAQ:ACHN) in a research note issued to investors on 5/18/17 to Outperform with price target of $0.

Additionally on 2/02/17 Ladenburg Thalmann “Initiates Coverage On” Achillion Pharmaceut (NASDAQ:ACHN) to Buy setting price target at $10 and on 11/04/16 Chardan Capital “Upgrades” the stock to Neutral. Furthermore on 9/22/16 Wedbush “Initiates Coverage on” the stock to Outperform at $13.

On the other hand the company has Relative Strength Index (RSI 14) of 50.91 along with Average True Range (ATR 14) of 0.22, Consequently Achillion Pharmaceut (NASDAQ:ACHN)’s weekly and monthly volatility is 4.82%, 5.62% respectively. The company’s beta value is at 1.98.

In terms of Buy, Sell or Hold recommendations, Achillion Pharmaceut (NASDAQ:ACHN) has analysts’ mean recommendation of 1.8. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Achillion Pharmaceut (NASDAQ:ACHN)’s minimum EPS for the current quarter is at $-0.17 and can go high up to $-0.15. The consensus mean EPS for the current quarter is at $-0.16 derived from a total of 6 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.14 earnings per share for the same quarter during last year.

Previously Achillion Pharmaceut (NASDAQ:ACHN) reported $-0.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.12 by $-0.03. The company posted an earnings surprise of -25%.

Currently Achillion Pharmaceut (NASDAQ:ACHN)’s shares owned by insiders are 15.78%, whereas shares owned by institutional owners are 89.6%. However the six-month change in the insider ownership was recorded 0.05%, as well as three-month change in the institutional ownership was recorded -0.81%.

Achillion Pharmaceut (NASDAQ:ACHN) 52-week high price stands at $9.49 and low price stands at $3.15, its price distance from 52-week high is -55.45% while its distance from 52-week low price is 34.29%. The stock hit its 52-week high on 08/24/16, and 52-week low on 04/24/17.

Achillion Pharmaceut (NASDAQ:ACHN)’s trailing twelve month revenues are $15 Million, whereas its price to sales ratio for the same period is 38.56. Its book value per share for the most recent quarter is $2.8 while its price to book ratio for the same period is 1.51, as for as the company’s cash per share for the most recent quarter is $2.77, however its price to cash per share ratio for the same period is 1.53. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.